GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) is a 1484-amino-acid protein with a mass of ~166 kDa . It forms heterotetrameric NMDA receptor complexes that regulate calcium influx and synaptic plasticity. GRIN2B dysfunction is linked to neurodevelopmental disorders such as autism, epilepsy, and schizophrenia . Antibodies targeting GRIN2B enable researchers to investigate its expression, post-translational modifications (e.g., phosphorylation), and role in disease models.
GRIN2B antibodies are validated for multiple techniques:
| Application | Reactivity | Clonal Type | Key Suppliers |
|---|---|---|---|
| Western Blot (WB) | Human, Mouse, Rat | Polyclonal/Monoclonal | Biocompare, Proteintech |
| Immunohistochemistry | Human, Mouse, Rat | Monoclonal | R&D Systems, BosterBio |
| ELISA, ICC, IF | Human | Polyclonal | Abbexa, NSJ Bioreagents |
Phospho-specific variants: Antibodies like Human/Rat/Primate Phospho-GRIN2B (Y1252) detect phosphorylation sites critical for NMDA receptor signaling .
Sensory Hypersensitivity: Grin2b C456Y/+ mice exhibit ACC (anterior cingulate cortex) hyperconnectivity and sensory hypersensitivity, reversible via chemogenetic suppression .
Neurodevelopmental Disorders: GRIN2B mutations correlate with altered synaptic plasticity and intellectual disability .
Early postnatal NMDAR stimulation in Grin2b mutants improves adult-stage hyperactivity and connectivity deficits, highlighting GRIN2B’s role in long-term brain function .
Dilution Range:
Validation: Western blots confirm specificity in brain lysates (e.g., rat hippocampus) .